O-(4-(trifluoromethyl)benzyl)hydroxylamine | 2993-57-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-(4-(trifluoromethyl)benzyl)hydroxylamine
• 英文别名: O-(4-trifluoromethylbenzyl)hydroxylamine；O-[4-(trifluoromethyl)benzyl]hydroxylamine；O-{[4-(trifluoromethyl)phenyl]methyl}hydroxylamine；O-[[4-(trifluoromethyl)phenyl]methyl]hydroxylamine
• CAS: 2993-57-9
• 化学式: C₈H₈F₃NO
• mdl: MFCD21641882
• 分子量: 191.153
• InChiKey: OSGYPUBYTWDYMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  O-(4-(trifluoromethyl)benzyl)hydroxylamine 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 O-[4-(三氟甲基)苄基]羟胺盐酸盐
  参考文献：
  名称：

  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

  摘要：

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.028
• 作为产物：
  描述：

  4-(三氟甲基)苄醇 在 偶氮二甲酸二异丙酯 、 一水合肼 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 O-(4-(trifluoromethyl)benzyl)hydroxylamine
  参考文献：
  名称：

  α-卤代羟肟酸盐与二硫化碳的碱促进形式[3 + 2]环加成合成多取代罗丹宁

  摘要：

  开发了一种简洁实用的策略，即通过 α-卤代异羟肟酸盐与常用溶剂二硫化碳的 [3 + 2]-环加成反应，以良好的收率合成功能化的罗丹宁衍生物。本方法具有广泛的底物范围以及良好的官能团耐受性。该协议的潜在合成效用通过合成一系列含有罗丹明骨架的天然产物衍生物来证明。

  DOI：

  10.1021/acs.orglett.2c00736

文献信息

• NOVEL VASCULAR LEAKAGEAGE INHIBITOR
  申请人：Industry-Academic Cooperation Foundation, Yonsei University

  公开号：US20140378399A1

  公开（公告）日：2014-12-25

  The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。
• Catalytic asymmetric aza-Michael addition of fumaric monoacids with multifunctional thiourea/boronic acids
  作者：Kenichi Michigami、Hiroki Murakami、Takeru Nakamura、Noboru Hayama、Yoshiji Takemoto

  DOI：10.1039/c9ob00045c

  日期：——

  synthesis of N-hydroxyaspartic acid derivatives using chiral multifunctional thiourea/boronic acid organocatalysts was developed. A series of fumaric monoacids underwent an intermolecular asymmetric aza-Michael addition of O-alkyl hydroxylamines in excellent regioselectivity. The addition of another carboxylic acid raised the enantiomeric enrichment up to 97% ee. O-Deprotection of the aza-Michael adduct

  开发了使用手性多功能硫脲/硼酸有机催化剂的N-羟基天冬氨酸衍生物的第一化学对映选择性合成。一系列富马酸单酸以优异的区域选择性进行了O-烷基羟胺的分子间不对称氮杂-Michael加成反应。添加另一种羧酸将对映体富集度提高到ee的97％。氮杂-迈克尔加合物的O-脱保护提供了适用于KAHA（α-酮酸-羟胺）连接的天冬氨酸衍生的羟胺片段。
• [EN] POLYHALOGENATED PROPENE BENZOQUINONE DIOXIME DERIVATIVES AND ITS USE AS PESTICIDES<br/>[FR] DERIVES DE PROPENE-BENZOQUINONE-DIOXIME POLYHALOGENES ET LEUR UTILISATION EN TANT QUE PESTICIDES
  申请人：BAYER CROPSCIENCE AG

  公开号：WO2006037496A1

  公开（公告）日：2006-04-13

  Novel dihalogenopropene derivatives of the formula (I) and of the formula (Ia), wherein A, A1, A2, G, Q, R1, R2, R3, R4, and X have the meaning provided in the description, Methods and intermediates for their production as well as their use for combattiing pests.

  具有以下公式(I)和公式(Ia)的新型二卤代丙烯衍生物，其中A、A1、A2、G、Q、R1、R2、R3、R4和X的含义如描述中所提供的含义，以及它们的生产方法和中间体，以及它们用于对抗害虫的用途。
• [EN] AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE<br/>[FR] ANALOGUES DE L'AFMT ET LEUR UTILISATION DANS DES MÉTHODES DE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：HARVARD COLLEGE

  公开号：WO2021216781A1

  公开（公告）日：2021-10-28

  The present disclosure provides compounds of formula (I), (II), and (la): Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.

  本公开提供了式(I)、(II)和(la)的化合物：描述了制备这些分子的方法以及它们用于治疗帕金森病的用途。
• NOVEL QUINOLONE DERIVATIVES
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20150299193A1

  公开（公告）日：2015-10-22

  The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

  本发明涉及通式(I)的新化合物、它们的互变异构体、对映异构体、药学上可接受的盐、含有它们的制药组合物、它们的制备方法、在医学中使用这些化合物以及它们的制备中所涉及的中间体。